MIPI Molecular Insight Pharmaceuticals (MM)

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that David S. Barlow, Chairman and Chief Executive Officer of Molecular Insight Pharmaceuticals, Inc., will present on two occasions at the 10th Annual BIO CEO & Investor Conference at the Waldorf=Astoria Hotel in New York, New York. On February 11, 2008, Mr. Barlow will participate in an opening plenary panel called, �Check Your Options: Raising Public and Private Financing in Today�s Marketplace�, where he will offer his expert insight on the current life sciences financing climate. On February 12, 2008, Mr. Barlow will present an overview of Molecular Insight and its pipeline of molecular radiotherapeutic and molecular imaging pharmaceutical candidates. Opening Plenary Panel �Check Your Options: Raising Public and Private Financing in Today�s Marketplace, Part II� Monday, February 11, 2008 4:15 pm - 5:30 pm Eastern Time Jade Room Molecular Insight Pharmaceuticals, Inc. Company Presentation Tuesday, February 12, 2008 9:30 am - 10:10 am Eastern Time Louis XVI Center The Molecular Insight company presentation will be webcast live at www.corporate-ir.net/ireye/conflobby.zhtml?ticker=MIPI&item_id=1752407 and will be archived for one year. It will also be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com. About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative, molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company�s lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com. Forward-Looking Statements Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of Azedra�, Onalta �, Zemiva� and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.